Abstract
Current therapeutic options, using sequential administering of two or more lines of targeted treatment with TKI and mTOR inhibitors, significantly prolonging lives of patients with metastasising kidney carcinoma - more than twice in median, permanent remissions are rare and therapy generally fails at some point. This is the reason for looking for further therapeutic procedures.
One way to improve the therapeutic results are efforts to personalise treatment, meaning finding predictive markers, which would enable to administer medication to patients selectively, depending on the probability of therapeutic response.